China’s National Medical Products Administration has approved Eli Lilly’s oral medicine orforglipron for adult weight management, the company announced on November 12, 2026; Reuters also reported the decision. The authorization covers adults with obesity, or adults with overweight and at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity.

What China’s approval covers

The company said the Chinese approval is for weight management in adults meeting the stated criteria, in combination with diet and physical activity. The announcement does not establish when the medicine will become available to patients in China or what it may cost there, so those details remain unconfirmed.

A separate diabetes indication is still under review

Lilly said its application in China for orforglipron to treat adults with type 2 diabetes remains under regulatory review. The weight-management authorization therefore should not be read as approval for that separate use.

How this fits the wider regulatory picture

Orforglipron has also received U.S. authorization: the U.S. Food and Drug Administration approved it earlier in 2026, according to the Associated Press. Each country’s regulator makes its own decision and sets the applicable authorized use; approval in one market does not determine launch timing, availability, or labeling in another.

For more reporting in this section, see The Globuzz Health coverage.

Sources: Reuters; Eli Lilly announcement via PR Newswire Asia; Associated Press on the U.S. FDA approval.